JP4223813B2 - 免疫増強特性を有するムチンペプチド - Google Patents

免疫増強特性を有するムチンペプチド Download PDF

Info

Publication number
JP4223813B2
JP4223813B2 JP2002576876A JP2002576876A JP4223813B2 JP 4223813 B2 JP4223813 B2 JP 4223813B2 JP 2002576876 A JP2002576876 A JP 2002576876A JP 2002576876 A JP2002576876 A JP 2002576876A JP 4223813 B2 JP4223813 B2 JP 4223813B2
Authority
JP
Japan
Prior art keywords
peptide
cells
sec
tumor
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002576876A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004532018A (ja
JP2004532018A5 (enExample
Inventor
ダイアナ エム． ロペス，
リン ハバート，
マントレイ ジュニア ドロシー，
ガンター クラウス，
ジェイムズ エイチ． ナツェン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Publication of JP2004532018A publication Critical patent/JP2004532018A/ja
Publication of JP2004532018A5 publication Critical patent/JP2004532018A5/ja
Application granted granted Critical
Publication of JP4223813B2 publication Critical patent/JP4223813B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2002576876A 2001-04-02 2002-04-02 免疫増強特性を有するムチンペプチド Expired - Fee Related JP4223813B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28013701P 2001-04-02 2001-04-02
PCT/US2002/010155 WO2002078607A2 (en) 2001-04-02 2002-04-02 Mucin peptide with immunoenhancing properties

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005109271A Division JP2005247861A (ja) 2001-04-02 2005-04-05 免疫増強特性を有するムチンペプチド

Publications (3)

Publication Number Publication Date
JP2004532018A JP2004532018A (ja) 2004-10-21
JP2004532018A5 JP2004532018A5 (enExample) 2005-12-22
JP4223813B2 true JP4223813B2 (ja) 2009-02-12

Family

ID=23071833

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002576876A Expired - Fee Related JP4223813B2 (ja) 2001-04-02 2002-04-02 免疫増強特性を有するムチンペプチド
JP2005109271A Withdrawn JP2005247861A (ja) 2001-04-02 2005-04-05 免疫増強特性を有するムチンペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2005109271A Withdrawn JP2005247861A (ja) 2001-04-02 2005-04-05 免疫増強特性を有するムチンペプチド

Country Status (11)

Country Link
US (2) US7285282B2 (enExample)
EP (1) EP1372691B1 (enExample)
JP (2) JP4223813B2 (enExample)
KR (1) KR20030092044A (enExample)
CN (1) CN1525864A (enExample)
AT (1) ATE376836T1 (enExample)
BR (1) BR0208771A (enExample)
CA (1) CA2443045A1 (enExample)
DE (1) DE60223232T2 (enExample)
NZ (1) NZ528234A (enExample)
WO (1) WO2002078607A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1301267C (zh) * 2005-06-21 2007-02-21 中国人民解放军军事医学科学院附属医院 Muc1粘蛋白的一个模拟表位肽及其编码dna与应用
WO2008093166A2 (en) * 2006-05-11 2008-08-07 Ghent University Sialoadhesin-related compositions and methods
CN112574283B (zh) * 2020-12-07 2022-07-05 湖北文理学院 一种人muc1特异性结合多肽及其提取方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.

Also Published As

Publication number Publication date
CN1525864A (zh) 2004-09-01
US7285282B2 (en) 2007-10-23
US20050095675A1 (en) 2005-05-05
DE60223232T2 (de) 2008-08-14
EP1372691A2 (en) 2004-01-02
JP2004532018A (ja) 2004-10-21
WO2002078607A2 (en) 2002-10-10
EP1372691B1 (en) 2007-10-31
BR0208771A (pt) 2004-07-06
WO2002078607A3 (en) 2003-03-27
ATE376836T1 (de) 2007-11-15
NZ528234A (en) 2006-01-27
JP2005247861A (ja) 2005-09-15
EP1372691A4 (en) 2005-11-09
CA2443045A1 (en) 2002-10-10
KR20030092044A (ko) 2003-12-03
US20030166853A1 (en) 2003-09-04
DE60223232D1 (de) 2007-12-13

Similar Documents

Publication Publication Date Title
KR100767554B1 (ko) 암 억제 유전자 더블유티1의 생산물에 기초한 암항원
US5750102A (en) Double transfectants of the MHC genes as cellular vaccines for immuno prevention of tumor metastasis
JP4723722B2 (ja) ワクチン用アジュバントとしてのｍｈｃクラスｉｉリガンドの使用および癌治療におけるｌａｇ−３の使用
TW201930340A (zh) 新抗原及其用途
CN109310739A (zh) 新抗原及其使用方法
ES2373055T3 (es) Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno.
JP2002504334A (ja) Ｏｘ−４０レセプター結合因子又はそれをコードする核酸を含む組成物並びに抗原特異的免疫応答を増強するための方法
JP4210519B2 (ja) 低免疫原性抗原の免疫原性を増強する医薬組成物
WO2017147160A1 (en) A universal cancer vaccine
JP2004523494A6 (ja) 低免疫原性抗原の免疫原性を増強する医薬組成物
RU2556128C2 (ru) Профилактическая противораковая вакцина
JP2013047230A (ja) Ｈｌａ−ａ２陽性者用ｈｓｐ１０５由来癌拒絶抗原ペプチド及びこれを含む医薬
JP4223813B2 (ja) 免疫増強特性を有するムチンペプチド
JP7585480B2 (ja) Ｐｄ－ｌ１の細胞外ドメインを含むキメラ抗原
KR20240109914A (ko) Trop2 면역원성 펩타이드
JP2010515670A (ja) 癌治療のための、手術、化学療法または放射線療法と併用した免疫療法におけるｍａｇｅａ３−プロテインｄ融合抗原の使用
AU2002304165B2 (en) Polynucleotide vaccine
JPH11512076A (ja) Ａｄｐ−リボシルトランスフェラーゼ活性を呈する組成物、及びその調製及び使用のための方法
TW201823267A (zh) 瘧疾疫苗
JP7513303B2 (ja) 腫瘍免疫増強剤、その調製方法および適用
AU2002307032A1 (en) Mucin peptide with immunoenhancing properties
US20040198684A1 (en) Vaccine comprising polynucleotides
ES2371394T3 (es) Antígenos de cáncer y su utilización.
HK1063726B (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20081028

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20081120

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111128

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees